Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study

Alberts, Steven R.; Townley, P.; Goldberg, Richard M.; S., S.; Sargent, Daniel J.; Moore, Dennis F.; Krook, James E.; Pitot, Henry C.; Fitch, Tom R.; Wiesenfeld, Martin; Mailliard, James A.

doi:10.1093/annonc/mdg170

Cited by 69 publications

(23 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The grade 3/4 thrombocytopenia rate of 70% reported in our study was substantially higher than that reported by other authors, with a reported range from 9 to 24% [11,17,18,19,20]. One possible explanation for this discrepancy is the higher dose of oxaliplatin used in our study, and another may be the heterogeneity of the cohorts in the different studies.…”

Section: Discussioncontrasting

confidence: 86%

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

et al. 2004

View full text Add to dashboard Cite

Objectives: The aimof this multicenter feasibility study was to determine the toxicity profile and antitumor activity of the gemcitabine plus oxaliplatin combination as second-line treatment in platinum plus paclitaxel resistant/refractory advanced ovarian cancer. Methods: Twenty patients received a 30–60-min infusion of gemcitabine a week for 2 weeks, followed by 120–180 min infusion of oxaliplatin every 3 weeks. The doses used were 1,000 and 130 mg/m², respectively. Seventeen cases (85% of the total) were platinum resistant and 3 (15%) were platinum refractory. Results: Grade 3/4 thrombocytopenia occurred in 14/20 of cases (70%); there were no symptomatic cases. 2 patients required platelet transfusion and 8 patients received hydrocortisone. The dose- limiting toxicity was thrombocytopenia. Combined grade 3/4 neutropenia was observed in 8/20 (40%) of cases (no sepsis was registered). Five patients were treated with recombinant erythropoietin because of grade 3 anemia and 4 cases received G-CSF prophylactically from the first cycle. The overall response rate of the combination in terms of antitumor activity was 26% (95% CI = 9–51%). Conclusion: A combination of gemcitabine and oxaliplatin using this schedule gave rise to a moderate/severe toxicity profile and would be feasible only if growth factors were used and/or gemcitabine were administered at lower doses. The antitumor activity of the combination was insufficient reward for the resultant toxicity profile. However, equivalent to that of other drugs used in platinum refractory and resistant patients.

show abstract

Section: Discussioncontrasting

confidence: 86%

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Encouraging results were obtained in some phase II trials using different schedules with an overall TTP from 3.6 to 5.7 and an OS from 5.6 to 9.5 months (37)(38)(39)(40)(41)(42)(43)(44)47). In particular, a preliminary trial assessed the combination of gemcitabine (1000 mg/m 2 as a 10 mg/m 2 /min infusion on day 1) plus oxaliplatin (100 mg/m 2 as a 2-h infusion on day 2 every two Table II.…”

Section: Gemcitabine and Capecitabinementioning

confidence: 95%

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

Marco¹

2010

Oncol Rep

118

View full text Add to dashboard Cite

Abstract. Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. Surgery remains the only treatment offering an advantage in terms of overall survival (5-year survival range, 15-25%), but unfortunately only 10-20% of patients present resectable disease at the time of diagnosis. Hence chemotherapy, possibly combined with radiation therapy, remains the only treatment option aimed at palliation of symptoms and ensuring a better quality of life. Notwithstanding the efforts to find more effective therapies for the treatment of pancreatic cancer, significant results have not yet been achieved. Increasing interest has focused on integrated treatments, i.e. chemotherapy combined with targeted therapies, and a better selection of patients. This study examines the principal clinical trials that will help give clinicians an overview of the progress made in the systemic therapy for advanced pancreatic cancer patients in recent years.

show abstract

“…Oxaliplatin-based regimen mostly used for treatment of metastatic colorectal and pancreatic cancers with promising results [17]- [20]. In our department, many regimens of chemotherapy were used to treat metastatic cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

Tharavichitkul¹,

Tharavichitkul²,

Chakrabandhu³

et al. 2016

JCT

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin ® ) 85 mg/m 2 D1, 5-Fluorouracil 400 mg/m 2 IV push D1-2, 5-Fluorouracil 600 mg/m 2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m 2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.

show abstract

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study

Abstract: Gemcitabine and oxaliplatin, at doses of 1000 mg/m(2) and 100 mg/m(2), respectively, showed moderate activity in patients with pancreatic ACA. Based on the results of this study further evaluation of this combination is warranted.

Cited by 69 publications

References 14 publications

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

Contact Info

Product

Resources

About